Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:PROK NASDAQ:SRRK NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$37.01-8.0%$40.85$16.50▼$48.45$3.75BN/A7,712 shs5,365 shsPROKProKidney$3.30+1.2%$2.57$0.46▼$7.13$959.36M1.722.82 million shs4.43 million shsSRRKScholar Rock$40.99+5.9%$33.99$22.71▼$46.98$3.72B0.422.84 million shs2.83 million shsZLABZai Lab$32.70-2.9%$33.54$23.82▼$44.34$3.77B1.08647,153 shs449,039 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-8.00%-6.96%-8.39%-3.22%+3,700,999,900.00%PROKProKidney+1.23%+18.71%+49.32%-27.31%+92.98%SRRKScholar Rock+5.94%+16.48%+29.80%+9.48%+47.61%ZLABZai Lab-2.94%-3.40%+3.84%-0.09%+32.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$37.01-8.0%$40.85$16.50▼$48.45$3.75BN/A7,712 shs5,365 shsPROKProKidney$3.30+1.2%$2.57$0.46▼$7.13$959.36M1.722.82 million shs4.43 million shsSRRKScholar Rock$40.99+5.9%$33.99$22.71▼$46.98$3.72B0.422.84 million shs2.83 million shsZLABZai Lab$32.70-2.9%$33.54$23.82▼$44.34$3.77B1.08647,153 shs449,039 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-8.00%-6.96%-8.39%-3.22%+3,700,999,900.00%PROKProKidney+1.23%+18.71%+49.32%-27.31%+92.98%SRRKScholar Rock+5.94%+16.48%+29.80%+9.48%+47.61%ZLABZai Lab-2.94%-3.40%+3.84%-0.09%+32.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/APROKProKidney 2.17Hold$6.2589.39% UpsideSRRKScholar Rock 3.07Buy$47.0014.66% UpsideZLABZai Lab 2.63Moderate Buy$56.3572.32% UpsideCurrent Analyst Ratings BreakdownLatest PROK, ZLAB, AAPG, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025SRRKScholar RockBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$53.0010/8/2025PROKProKidneyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SRRKScholar RockWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ZLABZai LabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PROKProKidneyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SRRKScholar RockWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ZLABZai LabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025SRRKScholar RockPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$52.00 ➝ $51.009/24/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $44.009/23/2025SRRKScholar RockHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $44.009/17/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M25.67N/AN/A$0.48 per share77.10PROKProKidney$80K12,139.05N/AN/A($3.41) per share-0.97SRRKScholar Rock$33.19M118.72N/AN/A$3.94 per share10.40ZLABZai Lab$398.99M9.16N/AN/A$7.68 per share4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/APROKProKidney-$61.19M-$0.57N/AN/AN/AN/AN/A-17.11%11/11/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)ZLABZai Lab-$257.10M-$2.04N/AN/AN/A-49.68%-27.32%-18.85%11/11/2025 (Estimated)Latest PROK, ZLAB, AAPG, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PROKProKidney-$0.14-$0.13+$0.01-$0.13N/A$0.22 million8/7/2025Q2 2025ZLABZai Lab-$0.37-$0.37N/A-$0.37$125.66 million$109.98 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53PROKProKidneyN/A11.4811.48SRRKScholar Rock0.216.336.33ZLABZai LabN/A3.122.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/APROKProKidney51.59%SRRKScholar Rock91.08%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/APROKProKidney41.49%SRRKScholar Rock13.30%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.17 millionN/AN/APROKProKidney3294.28 million172.18 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableZLABZai Lab1,869111.76 million106.22 millionOptionablePROK, ZLAB, AAPG, and SRRK HeadlinesRecent News About These CompaniesStocks Showing Improved Relative Strength: Zai Lab ADROctober 9 at 1:17 PM | msn.comWeiss Ratings Reaffirms Sell (D-) Rating for Zai Lab (NASDAQ:ZLAB)October 8 at 1:06 PM | marketbeat.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 8 at 4:45 AM | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?September 30, 2025 | marketbeat.comZai Lab (ZLAB) Gets a Buy from Cantor FitzgeraldSeptember 21, 2025 | theglobeandmail.com29,693 Shares in Zai Lab Limited Unsponsored ADR $ZLAB Purchased by Acadian Asset Management LLCSeptember 18, 2025 | marketbeat.comZai Lab Limited (ZLAB): A Bull Case TheorySeptember 16, 2025 | finance.yahoo.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 15, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Insider Buys $289,100.00 in StockSeptember 14, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's What HappenedSeptember 13, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Insider Acquires $289,100.00 in StockSeptember 13, 2025 | insidertrades.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's WhySeptember 12, 2025 | marketbeat.comZai Lab's Double Whammy: Earnings Miss, Phase 3 SetbackSeptember 11, 2025 | benzinga.comWoodline Partners LP Lowers Stock Holdings in Zai Lab Limited Unsponsored ADR $ZLABSeptember 11, 2025 | marketbeat.comZai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab ...September 6, 2025 | bakersfield.comBInstitutional investors may overlook Zai Lab Limited's (NASDAQ:ZLAB) recent US$260m market cap drop as long-term gains remain positiveSeptember 6, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLABSeptember 6, 2025 | globenewswire.comAmgen’s bemarituzumab loses momentum as survival edge fadesSeptember 5, 2025 | thepharmaletter.comTZai Lab to wait on results of FORTITUDE-102 prior to regulatory filingSeptember 3, 2025 | msn.comZai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer DrugSeptember 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePROK, ZLAB, AAPG, and SRRK Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$37.01 -3.22 (-8.00%) As of 10/9/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.ProKidney NASDAQ:PROK$3.30 +0.04 (+1.23%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$3.28 -0.02 (-0.61%) As of 06:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Scholar Rock NASDAQ:SRRK$40.99 +2.30 (+5.94%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$41.84 +0.85 (+2.07%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Zai Lab NASDAQ:ZLAB$32.70 -0.99 (-2.94%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$32.76 +0.06 (+0.20%) As of 10/9/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
